combining agents to improve response rates in genitourinary cancer
Published 7 years ago • 66 plays • Length 2:40Download video MP4
Download video MP3
Similar videos
-
1:44
improving responses to immunotherapy in metastatic pancreatic cancer
-
5:06
state of the art research in bladder cancer treatment
-
0:44
role of immunotherapy in bladder cancer
-
3:39
tgf-β/emt gene signature in low-responders to pembrolizumab
-
1:10
the difficulties in treating bladder cancer with immunotherapy
-
1:14
how can we continue the success of checkpoint inhibitors for bladder cancer treatment?
-
1:03
dr. grivas on combination strategies in genitourinary cancer
-
4:35
highlights from asco gu 2022
-
56:42
genitourinary cancers with dr. padmini moffett
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
0:44
unmet needs in bladder cancer in the immunotherapy era
-
3:51
is pembrolizumab alone sufficient to treat bladder cancer?
-
3:44
immunotherapy as combination and neoadjuvant therapies in nsclc
-
5:44
hcrn-gu16-260: nivolumab and salvage nivolumab-ipilimumab in patients with advanced rcc
-
1:23
targeting the unfolded protein response to treat cancer
-
2:52
enfortumab vedotin in urothelial cancer
-
2:27
combining avelumab and axitinib in advanced renal cell carcinoma (rcc)
-
1:44
adcs in the treatment landscape of patients with advanced uc
-
1:10
highlights in bladder cancer from asco 2022